Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

JACC: Basic to Translational Science

Volumn 3, Issue 5, 2018, Pages 575-587

  Verma, Subodh ^a   Rawat, Sonia ^b   Ho, Kim L ^b   Wagg, Cory S ^b   Zhang, Liyan ^b   Teoh, Hwee ^a   Dyck, John E ^b   Uddin, Golam M ^b   Oudit, Gavin Y ^b   Mayoux, Eric ^c   Lehrke, Michael ^d   Marx, Nikolaus ^d   Lopaschuk, Gary D ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

cardiac efficiency; db db; glucose oxidation; ketone oxidation

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 3 HYDROXYBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; EMPAGLIFLOZIN; FATTY ACID; GLUCOSE; INSULIN; KETONE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MALONYL COENZYME A; PALMITIC ACID; PYRUVATE DEHYDROGENASE KINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY YIELD; EXPERIMENTAL DIABETES MELLITUS; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FAILURE; HEART FUNCTION; HEART OUTPUT; HEART PERFUSION; HEART WORK; ISOLATED HEART; MALE; METABOLIC RATE; MOUSE; NONHUMAN; PROTEIN ACETYLATION; PROTEIN EXPRESSION; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 85057150416     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2018.07.006     Document Type: Article

References (37)

1. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Neal, B., Perkovic, V., Mahaffey, K.W., et al. CANVAS Program Collaborative Group, Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
3. Farkouh, M.E., Verma, S., Prevention of heart failure with SGLT-2 inhibition: insights from CVD-REAL. J Am Coll Cardiol 71 (2018), 2507–2510.
4. Cavender, M.A., Norhammar, A., Birkeland, K.I., et al., CVD-REAL Investigators and Study Group. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol 71 (2018), 2497–2506.
5. Verma, S., Mazer, C.D., Al-Omran, M., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137 (2018), 405–407.
6. Verma, S., Mazer, C.D., Fitchett, D., et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial. Diabetologia 61 (2018), 1712–1723.
7. Verma, S., McMurray, J.J.V., SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 2018 In press.
8. Verma, S., McMurray, J.J.V., Cherney, D.Z.I., The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2 (2017), 939–940.
9. Shi, X., Verma, S., Yun, J., et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. Mol Cell Biochem 433 (2017), 97–102.
10. Verma, S., Garg, A., Yan, A.T., et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?. Diabetes Care 39 (2016), e212–e213.
11. Byrne, N.J., Parajuli, N., Levasseur, J.L., et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. J Am Coll Cardiol Basic Trans Science 1 (2017), 347–354.
12. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol Rev 90 (2010), 207–258.
13. Wende, A.R., Brahma, M.K., McGinnis, G.R., Young, M.E., Metabolic origins of heart failure. J Am Coll Cardiol Basic Trans Science 2 (2017), 297–310.
14. Singh, K.K., Shukla, P.C., Yanagawa, B., et al. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg 146 (2013), 702–709.
15. Fukushima, A., Zhang, L., Huqi, A., et al. Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight, 3, 2018, 99239.
16. Karwi, Q.G., Uddin, G.M., Ho, K.L., Lopaschuk, G.D., Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med, 5, 2018, 68.
17. Mori, J., Patel, V.B., Abo Alrob, O., et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 7 (2014), 327–339.
18. Zhabyeyev, P., Gandhi, M., Mori, J., et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97 (2013), 676–685.
19. Mori, J., Alrob, O.A., Wagg, C.S., Harris, R.A., Lopaschuk, G.D., Oudit, G.Y., ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 304 (2013), H1103–H1113.
20. Huss, J.M., Kelly, D.P., Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115 (2005), 547–555.
21. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
22. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
23. Lopaschuk, G.D., Verma, S., Empagliflozin's fuel hypothesis: not so soon. Cell Metab 24 (2016), 200–202.
24. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
25. Basu, R., Oudit, G.Y., Wang, X., et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 297 (2009), H2096–H2108.
26. Larsen, T.S., Belke, D.D., Sas, R., et al. The isolated working mouse heart: methodological considerations. Pflugers Arch 437 (1999), 979–985.
27. Lopaschuk, G.D., Witters, L.A., Itoi, T., Barr, R., Barr, A., Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart. J Biol Chem 269 (1994), 25871–25878.
28. Buchanan, J., Mazumder, P.K., Hu, P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
29. Mazumder, P.K., O'Neill, B.T., Roberts, M.W., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53 (2004), 2366–2374.
30. Alrob, O.A., Sankaralingam, S., Ma, C., et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res 103 (2014), 485–497.
31. Dyck, J.R., Barr, A.J., Barr, R.L., Kolattukudy, P.E., Lopaschuk, G.D., Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 275 (1998), H2122–H2129.
32. Ozden, O., Park, S.H., Wagner, B.A., et al. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radic Biol Med 76 (2014), 163–172.
33. Randle, P.J., Garland, P.B., Hales, C.N., Newsholme, E.A., The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 281 (1963), 785–789.
34. Sherman, S.E., Bell, G.O., Teoh, H., et al. Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. J Am Coll Cardiol Basic Trans Science 3 (2017), 327–329.
35. Packer, M., Anker, S.D., Butler, J., Filippatos, G., Zannad, F., Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2 (2017), 1025–1029.
36. Uthman, L., Baartscheer, A., Bleijlevens, B., et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61 (2018), 722–726.
37. Javadov, S., Huang, C., Kirshenbaum, L., Karmazyn, M., NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J Mol Cell Cardiol 38 (2005), 135–143.